Current Report Filing (8-k)
31 August 2017 - 5:10PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported)
August 30, 2017
AMAIZE
BEVERAGE CORPORATION
(exact
name of registrant as specified in its charter)
Nevada
(State
or other jurisdiction of incorporation)
333-59114
|
|
33-0730042
|
Commission
File Number
|
|
IRS
Employer
Identification Number
|
5042
Wilshire Blvd. Los Angeles, CA
|
|
90036
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
(949) 287-3164
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (SEE General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
ITEM
5.07. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
The
majority shareholders of Amaize Beverage Corporation, a Nevada corporation (the “Registrant”) constituting a total
of 9,180,143 shares of common stock (58.44%) approved as of August 29, 2017, in a written consent of the majority of the shareholders
of the Registrant as of the same date, a name change from its current name to “Curative Biosciences, Inc.”.
The
Registrant believes that its new name will better reflect the new direction of the Company’s business which will focus on
the research, development, and sale of high-quality, natural products supported by clinical research designed
to provide effective relief from common concerns. The products will include medical grade arthritis relief supplements and topical applications, pain relief supplements and topical
applications, and supplements providing relief from anxiety and depression.
Following
the required regulatory approval and the filing of the amended articles of incorporation of the Registrant, the Registrant will
announce the effective date of the name change.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
|
AMAIZE
BEVERAGE CORP.
|
|
|
Dated:
August 31, 2017
|
By:
|
/s/
Richard Damion
|
|
|
Richard
Damion
|
|
|
Chief
Executive Officer
|
Curative Biosciences (CE) (USOTC:CBDX)
Historical Stock Chart
Von Okt 2024 bis Nov 2024
Curative Biosciences (CE) (USOTC:CBDX)
Historical Stock Chart
Von Nov 2023 bis Nov 2024
Echtzeit-Nachrichten über Curative Biosciences Inc (CE) (OTCMarkets): 0 Nachrichtenartikel
Weitere Amaize Beverage Corp News-Artikel